Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study published in the Bulletin of the World Health Organization describes a plausible range for the risk of microcephaly in women who were infected with Zika virus during pregnancy compared to those who were not infected.

Image courtesy of Shutterstock

Investigators obtained data on the number of notified and confirmed microcephaly cases in each Brazilian state between November 2015 and October 2016 from the health ministry. For Pernambuco State, one of the hardest hit, weekly data were available from August 2015 to October 2016 for different definitions of microcephaly.

Read more (ISARIC website)

About ISARIC 

ISARIC – the International Sever Acute Respiratory and emerging Infection Consortium – is part of ZIKAlliance, a multinational and multi-disciplinary research consortium comprised of 53 partners worldwide and funded by the European Union's Horizon 2020 Research and Innovation Programme. The consortium focuses on the impact of ZIKV infection during pregnancy and the natural history of ZIKV in humans and their environment. In collaboration with two other EU-funded consortia (ZikaPLAN and ZIKAction), ZIKAlliance is working to develop a preparedness platform in Latin America and the Caribbean. 

ISARIC’s Coordinating Centre - based at the Centre for Tropical Medicine and Global Health in Oxford University's NDM Research Building - is leading on the activities of work package 8 (Communication, Dissemination, and Evaluation), and co-leading work package 11 (ZIKA COLLAB).

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.

Opportunities for final goodbyes must be prioritised in COVID-19 pandemic

Coronavirus COVID-19 General Research

Bereaved relatives described the ongoing pain of being absent at the end of a loved-one's life. Many had not seen their relative for weeks or months due to the pandemic. Opportunities must be prioritised for essential connections between families at end-of-life care.